Pharsight

Belsomra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(9 years from now)

Belsomra is owned by Merck Sharp Dohme.

Belsomra contains Suvorexant.

Belsomra has a total of 2 drug patents out of which 0 drug patents have expired.

Belsomra was authorised for market use on 13 August, 2014.

Belsomra is available in tablet;oral dosage forms.

Belsomra can be used as treatment of insomnia.

Drug patent challenges can be filed against Belsomra from 13 August, 2018.

The generics of Belsomra are possible to be released after 29 May, 2033.

Drug Exclusivity Drug Exclusivity Expiration
M(M-253) Jan 29, 2023
New Chemical Entity Exclusivity(NCE) Aug 13, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using SUVOREXANT ingredient

NCE-1 date: 13 August, 2018

Market Authorisation Date: 13 August, 2014

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

BELSOMRA family patents

Family Patents